The present invention provides an
allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic
disease and can safely and effectively induce
immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic
disease for the prevention or treatment of the allergic
disease. The vaccine composition contains: an immunomodulator which is a
lipopolysaccharide derived from at least one
gram-negative bacterium selected from the group consisting of
Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus,
Gluconacetobacter,
Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia,
Pseudomonas,
Achromobacter, Bacillus, Methanoculleus, Methanosarcina,
Clostridium,
Micrococcus,
Flavobacterium,
Pantoea,
Acetobacter,
Zymomonas,
Xanthomonas, and
Enterobacter, or a salt of the
lipopolysaccharide; and at least one
allergen.